108 results about "Human plasma" patented technology

Provided herein are compositions comprising allogeneic human plasma and platelet derived product, and methods for making the compositions and using the compositions as a therapeutic for example, in orthopedic indications.

The invention discloses a novel high performance liquid chromatography-tandem mass spectrometry analysis method for detecting aspartatide in human plasma, teriparatide is used as an internal standard substance to be detected, a solid phase extraction method is adopted to extract aspartatide to be detected and internal standard teriparatide from a plasma sample, and a standard curve is linear in a range of 0.010-1.00 ng / mL. During the verification of the method, selectivity, matrix effect, recovery, sensitivity, linearity, accuracy and precision, stability and dilution reliability are assessed to meet standards. The method disclosed by the invention has specificity on determination of the to-be-detected substance, i.e., the aspartatide and the internal standard teriparatide in the human plasma, and a standard curve is linear in a range of 0.010-1.00 ng / mL. The quantitative lower limit of methodology is 0.01 ng / mL. The method has the advantages of good accuracy, reliability, high sensitivity, high specificity and reproducibility.

The invention relates to the field of blood products, in particular to a preparation method of human activated C1 esterase. The preparation method comprises the following steps: carrying out contact adsorption on cryoprecipitate-removed human plasma and anion exchange resin, washing and eluting to obtain an eluent containing C1 proesterase, carrying out membrane filtration, and carrying out ultrafiltration desalination treatment; adding an anionic substance into the eluent, incubating in vitro to effectively activate the C1 esterase, and filtering by a membrane to obtain a feed liquid containing the activated C1 esterase; and carrying out purification treatment on the feed liquid to obtain the human activated C1 esterase, and carrying out cryopreservation. According to the method, an anion substance is introduced into an eluent system obtained through anion exchange, mild and effective activation of the C1 proesterase is achieved under the condition of not depending on foreign proteolytic enzyme, the risk of non-specific hydrolysis and self-cutting inactivation is remarkably reduced, good synergy is formed with a follow-up purification process, and the method is suitable for industrial production. The human activated C1 esterase product with relatively high activity and good stability is obtained.

The invention relates to the technical field of medicine analysis, in particular to a method for determining the concentration of tigliptin in human plasma through liquid chromatography-tandem mass spectrometry. Wherein a mobile phase of the liquid chromatography comprises an acetic acid aqueous solution and acetonitrile; at 0-0.8 min, the volume content of acetonitrile in the mobile phase is 15-40%; when the time is 0.8-1.2 min, the volume content of acetonitrile in the mobile phase is 80-95%; after 1.2 min, the volume content of acetonitrile in the mobile phase is 15-40%. By optimizing chromatographic conditions, mass spectrum parameters and other steps, the detection process is simplified, the detection efficiency is improved, the operation difficulty and cost are reduced, the efficient and accurate tigliptin drug concentration detection method is provided, the concentration of tigliptin in plasma can be accurately determined, and the accuracy and reliability of data are ensured.

FIELD: pharmacology.SUBSTANCE invention can be used to determine the concentration of an anti-tuberculosis drug in blood serum. The method for determining the concentration of bedaquiline in the blood serum in patients with tuberculosis or mycobacteriosis is that whole blood samples are centrifuged at 3000 rpm for 20 minutes, then the blood plasma is collected in sterile 1.5 mL Eppendorf tubes, then 900 mcL of acetonitrile are added to 300 mcL of plasma and centrifuged at 13500g for 15 minutes, then 1 mL of the supernatant is transferred to a chromatographic vial and make the assay by UHPLC MS / MS using an Athena UHPLC C18, 1.8 mcM, 120A, 2.1×100 mm chromatography column, when using an aqueous solution containing 5 g / L of ammonium acetate, 25 ml / L of concentrated acetic acid, 2 ml / L trifluoroacetic acid as mobile phase A and 100% acetonitrile as mobile phase B, the concentration of bedaquiline is determined using a pre-plotted calibration curve.EFFECT: determination of bedaquiline in human blood plasma in a time not exceeding 6 minutes.1 cl, 9 dwg, 6 tbl

The invention relates to the technical field of pollution treatment equipment, and discloses a syphilis patient plasma pollutant treatment device which comprises a bottom plate, and a mounting frame is fixedly connected to the middle of the top end of the bottom plate; the electromagnetic separation mechanism is arranged in the middle of the top end of the mounting frame and used for separating plasma pollutants of the syphilis patient in an electromagnetic treatment mode; and the regeneration and recovery mechanism is arranged on one side of the top of the mounting frame. By adding and arranging the regeneration and recovery mechanism, when plasma pollutants of syphilis patients are treated, the mechanism can thoroughly recover magnetic nanoparticles in a quartz separation column through flexible switching of conveying of eluent and regeneration liquid through a first three-way solenoid valve, precise liquid supply through combination of a first conveying pump and auxiliary elution through cooperation of an ultrasonic oscillator; and the compound and the particles can be separated through centrifugal treatment of the centrifugal cylinder, the regeneration liquid can enable the particles to be renatured and restore activity, and reutilization is achieved.

The invention provides a method for detecting the drug concentration of bevacizumab. The method comprises the following steps: taking a solution containing infliximab as an internal standard working solution, and determining the drug concentration of the bevacizumab in a sample to be detected by adopting liquid chromatography-tandem mass spectrometry. In drug monitoring for clinical detection of the bevacizumab concentration in human plasma, infliximab is adopted as an internal standard, the detection requirement can be effectively met, and the detection cost is reduced. The infliximab serves as an internal standard, methodological requirements of the established method can be met, and accuracy and reliability of detection results are ensured. In addition, by optimizing the sample pretreatment process, the operation steps are simplified, the detection time is shortened, manual operation errors are reduced, and the detection accuracy and efficiency are further improved.

The present invention discloses a method and a kit for determining the concentration of olverembatinib in human plasma or cerebrospinal fluid based on LC-MS / MS. First, working solutions of olverembatinib standard curves with different concentrations and working solutions of olverembatinib quality controls with different concentrations are prepared. Then, an internal standard working solution is configured. Finally, the internal standard working solution is added to the sample to be tested, vortexed and mixed, and then pretreated to obtain a supernatant. The supernatant is taken and injected into an LC-MS / MS instrument for detection and analysis. The present invention not only has simple pretreatment, low cost, short analysis time, and good specificity, but also has high sensitivity of the detection method, and the lower limit of quantification can reach the picogram level, which is rare in other LC-MS / MS detection methods. This method can be used for the pharmacokinetic-pharmacodynamic study of olverembatinib and the determination of the concentration of olverembatinib in the plasma and cerebrospinal fluid of conventional clinical patients.

Provided herein are, inter alia, protease-activatable cytokines, as well as uses and methods of treatment. In particular, protease-activatable IL-12 fusion proteins, where the two subunits p40 and p35 are produced as fusion proteins with at least one masking moiety (Mask) linked to the subunit by a release segment (RS), namely, a cleavable linker, especially (i) not cleavable by legumain in human plasma, (ii) cleaved less than 25% compared to EAGRSANHTPAGLTGP (RSR-2295; SEQ ID NO:7048, legumain target) or, (iii) where the release segment comprises EAGRSAXHTPAGLTGP, X is any amino acid other than N (SEQ ID NO:7627). In preferred embodiments, each of the IL-12p35 and IL-12p40 subunits are linked at the N-and C-terminal ends by release segments (cleavable linker) to different masking moieties (Masks). In some embodiments, the fusion proteins further comprise barcodes.

The present invention provides a method of fractionating human plasma, in some embodiments, using the Cohn fractionation procedure. The improvement comprises the use of physiologically active concentrated plasma as the starting material for the fractionation procedure.

The invention relates to the technical field of drug monitoring, and mainly relates to a method for detecting multiple antitumor drugs and metabolites in human plasma through liquid chromatography-tandem mass spectrometry and application of the method. The medicine to be detected is prepared from cevaltinib, loratinib, vomitinib, amitinib, sovantinib, anlotinib, glutamitinib, emtricitinib, N-demethylated vomitinib and N-demethylated emtricitinib; s2, preparing a calibration product and a quality control product, and preparing a working curve concentration table; s3, carrying out pretreatment on the calibration product and the quality control product obtained in the step S2; s4, carrying out liquid chromatography-tandem mass spectrometry detection on the pretreated liquid; and S5, performing methodological verification on the detection method. The detection method has the advantages of high sensitivity, good detection result accuracy, simple and rapid detection process, short analysis time and the like, and is suitable for detection of large-flux samples.

A process for synthesizing and separating secretory IgA from a mixture of IgA monomer and IgA dimer is provided The process includes covalently binding affinity tagged or epitope tagged recombinant secretory component to the IgA dimer in the mixture and then binding the affinity tagged or an epitope tagged secretory IgA to immobilized moieties on the solid phase support resin to which the affinity tag or epitope tag binds and then eluting the affinity tagged or an epitope tagged secretory IgA with release buffer. A process for synthesizing and separating secretory IgM from a mixture of IgM and other plasma proteins is provided. A process is provided for inhibiting or preventing symptoms of necrotizing enterocolitis in a subject that includes the oral administration to the subject of a human polyclonal secretory IgA formed by the conjugation of human recombinant secretory component and pooled human plasma derived dimeric and polymeric.

The invention relates to a method for extracting human alpha1-antitrypsin from plasma by a full chromatography method. According to the method, specifically, human plasma or a flow-through liquid obtained after Pg, Fg, IgG and Alb are sequentially extracted from the human plasma is used as a raw material, chromatography preparation is conducted through a two-step chromatography method of CM FF cation exchange chromatography and DEAE FF ion exchange chromatography, according to the method, the yield of human alpha1-antitrypsin is larger than 400 g on the basis of 1000 L of plasma, and the relative purity of a product is larger than 99%.

The invention relates to a method for measuring the concentration of cefadroxil in K2EDTA human plasma through LC-MS / MS. The method comprises the following steps: preparing a standard curve solution containing cefadroxil d4 by taking K2EDTA human plasma as a matrix, preparing a test solution containing cefadroxil, and precipitating the solution by using acetonitrile; determining the concentration of the test solution containing cefadroxil after precipitation by using an internal standard method; a liquid chromatography tandem mass spectrometer is used for determination, a mobile phase of liquid chromatography is composed of a mobile phase A and a mobile phase B, the mobile phase A is an acetic acid aqueous solution, and the mobile phase B is acetonitrile; the elution procedure of the liquid chromatography is isocratic elution, the volume content of acetonitrile in a mobile phase is 10-30%, and the flow velocity of the mobile phase is 0.4-0.8 mL / min. By optimizing chromatographic conditions and mass spectrum parameters, an efficient and accurate cefadroxil concentration detection method is provided, and the accuracy and reliability of data are ensured.

The invention provides a photoelectrochemical biosensor for detecting exosome lncRNA as well as a construction method and application of the photoelectrochemical biosensor. Specifically, an ITO / COF / TiO2 electrode prepared from photoelectric active material COF nanospheres and TiO2 nanospheres generates initial light current under light excitation in a visible light range. Then the electrode is assembled step by step, porous active sites of the TiO2 nanospheres on the surface of the electrode are sealed by pDNA of which the 3'end is modified with a phosphate group, and the phosphate group can ensure that the pDNA is not influenced by subsequent TdT. Then, target lncRNA competes for pDNA on the electrode through base complementary pairing to expose a site, and Tyr can be adsorbed on the surface of the electrode through the pores of the TiO2 nanospheres. TdT catalyzes dCTP, poly (C) is generated in situ on the surface of the electrode by taking a phenolic hydroxyl group of Tyr as a polymerization site, NaBH4 is used for reducing AgNO3 to generate DNA-AgNCs, and the DNA-AgNCs strengthens a photocurrent signal through an SPR (Surface Plasmon Resonance) effect. The sensor has high selectivity and high sensitivity for detecting the content of lncRNA in human plasma exosome lysate, and has huge application potential for biomarker detection in early diagnosis of lung cancer.

The present application relates to a kind of HPLC-MS / MS detection method of detecting in human plasma, desloratadine and 3-hydroxydesloratadine in human plasma, it includes the following steps: (1) human plasma sample pretreatment;(2) liquid chromatography-mass spectrometry detection, using mobile phase A and mobile phase B as mixed mobile phase is carried out gradient elution, wherein: mobile phase A is methanol-acetonitrile mixed solution, in mixed solution methanol and acetonitrile volume ratio is 4-6:6-4;Mobile phase B is 2-20mM ammonium formate aqueous solution;(3) the determination of the concentration of human plasma in lopatadine, desloratadine and 3-hydroxydesloratadine.The present application uses lopatadine-d4, desloratadine-d5, 3-hydroxydesloratadine-d4 as deuterium internal standard, using Agilent, ZORBAX Eclipse XDB-Phenyl is carried out gradient elution, deuterium internal standard and the measured substance has the same retention time, chemical property and matrix effect, the reproducibility, accuracy of determining the concentration of lopatadine, desloratadine and 3-hydroxydesloratadine in plasma are good.The method of the present application can be used to evaluate the bioequivalence of lopatadine.

The invention discloses a method for detecting the concentration of Hetrombopag in human plasma through high performance liquid chromatography-tandem mass spectrometry. The method comprises the following steps: adding an internal standard Eltrombopag-13C4 and a precipitator into a plasma sample, uniformly mixing, centrifuging, and taking a supernatant; performing high performance liquid chromatography-tandem mass spectrometry detection on the supernate, and calculating by combining a standard curvilinear equation to obtain the concentration of the Hytrombopag in the human plasma. Through methodology verification of specificity, accuracy, precision, matrix effect, dilution reliability, residue, stability and the like, the detection method can be applied to detection analysis and pharmacokinetic research of a clinical patient hitrombopag plasma sample, so that the use dosage of the medicine is reasonably adjusted, and a safer and more effective individualized medication scheme is provided for the patient.

The invention discloses a high-sensitivity Tau-441 electrochemical immunosensor based on a nano material synergistic amplification effect as well as a preparation method and application of the high-sensitivity Tau-441 electrochemical immunosensor. According to the sensor, a silk-screen printing electrode (SPE) is used as a substrate, a PEDOT: PSS / MWCNTs-COOH nanocomposite modified working electrode is used as a sensing platform, and electron transfer is promoted by using the large specific surface area and excellent conductivity of the PEDOT: PSS / MWCNTs-COOH nanocomposite modified working electrode. Meanwhile, gold-modified magnetic nanoparticles (Fe3O4-coated AuNPs) are prepared as a signal probe, and the magnetic separation and enrichment function of Fe3O4 and the biocompatibility and catalytic activity of the gold nanoparticles are combined. The sandwich immune complex is constructed by adopting a homogeneous reaction mode, so that the mass transfer resistance is effectively reduced, and the detection time is shortened. The sensor has an extremely low detection limit (19.68 fgmL <-1 >) and a wide linear range on an Alzheimer's disease marker Tau-441, is high in specificity and good in stability, and is suitable for early-stage rapid screening of human plasma samples.

Inventors describe herein the functional and structural characteristics of the MGL from the anaerobic alkaliphilic thermophile Thermobrachium celere (TcMGL), which was compared to that from Pseudomonas putida (PpMGL). Catalysis was limited to L-Met, L-homocysteine, and L-cysteine, with the highest catalytic efficiency (keat / KM) towards L-Met. The half-life of active TcMGL in human plasma at 37°C was 9.2 hour. Half-life increased from 11.3 hour to 66.7 hour with increasing PLP concentration from 2 to 200 µM, in much greater magnitude than in PpMGL case. TcMGL crystal structure resolution revealed that the enzyme is a tetramer of two catalytic dimers containing a mobile region with open and closed conformations resulting in differences for access to the active site. TcMGL possesses favourable characteristics which makes it a suitable candidate for treatment of cancer. The present invention relates to a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO: 1 or a function-conservative variant thereof.

The invention belongs to the technical field of biological detection, and particularly relates to a non-invasive selenium level prediction method based on saliva selenoprotein P detection and application. According to the invention, a heterologous expression antigen SELENOP (40-194aa) is used for immunizing a mouse to generate an antibody, and the monoclonal antibody capable of efficiently recognizing SELENOP is obtained through screening; and establishing an ELISA detection method by using the obtained monoclonal antibody. By utilizing the detection method and an ICP-MS selenium content detection method, the selenoprotein P content in human plasma and saliva and the total selenium content in the plasma are detected and analyzed, and obvious positive correlation exists among the selenoprotein P content, the saliva selenoprotein P content and the total selenium content in the plasma, so that a correlation curve between the selenoprotein P in the saliva and the selenium content in the human plasma is established; and thus, the aim of non-invasively detecting and evaluating the selenium level of the human body through the saliva selenoprotein P is fulfilled. The technical scheme provided by the invention can be used for large-scale screening and conventional health monitoring.

The invention discloses a method for extracting protein from human plasma for protein analysis, and relates to the technical field of plasma treatment, the key points of the technical scheme are as follows: the method effectively removes high-abundance protein, lipid and other interfering substances in the plasma through two steps of protein precipitation with acetone, degreasing and high-abundance protein removal; the method is suitable for subsequent protein identification and quantitative analysis. A stable and reliable method is provided for pretreatment of the plasma sample, a technical basis is provided for further use of protein in plasma for various medical analyses, and further development of the technology in the plasma detection field is facilitated.

The present application relates to a kind of PLOD2 gene and / or protein as biomarker in the application of preparation auxiliary MASH detection kit.It is also provided that the reagent for detecting the expression amount of PLOD2 in sample is applied to the preparation of auxiliary detection MASH detection kit.The present application finds that the content of PLOD2 in the plasma exosome of patient with metabolic dysfunction-related steatohepatitis is up-regulated, suggesting that the plasma or serum exosome rich in PLOD2 can be used as a new non-invasive biomarker, which can be used for early diagnosis and early treatment of auxiliary MASH patient, and for the progress research and drug research of MASH.

Methods are provided for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-parvo B19 immunoglobulin G. The methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-parvo B19 immunoglobulin G are also provided. Methods for treating parvo B19 infections by administration of plasma-derived IgG compositions highly enriched for anti-parvo B19 immunoglobulin G are also provided.

The invention relates to the technical field of analysis and detection, in particular to a kit and a method for extracting catecholamine and metabolites thereof based on a paramagnetic particle method and a method for detecting catecholamine and metabolites thereof by LC-MS / MS (liquid chromatography-mass spectrometry / mass spectrometry). The kit comprises magnetic beads, an activating solution, an eluent, a washing solution, a leacheate I, a leacheate II and a derivatization reagent, the catecholamine and the metabolite thereof comprise one or more of dopamine hydrochloride, epinephrine, noradrenaline hydrochloride, methoxynoradrenaline hydrochloride, methoxyepinephrine hydrochloride and 3-methoxytyramine hydrochloride. The in-vivo concentration of catecholamine and metabolites thereof in human plasma and urine is detected in a high-flux manner by adopting a magnetic bead and derivation method, and the kit has the characteristics of high sensitivity, good repeatability, high accuracy, good specificity and the like.

The application relates to a method for quantitatively detecting the concentration of thioctic acid in human plasma by liquid chromatography-tandem mass spectrometry, and belongs to the technical field of biological sample detection. The method comprises the following steps: EDTA-K2 anticoagulant human plasma is taken, thioctic acid-d5 internal standard working solution is added, the mixture is uniformly mixed, acetonitrile is added to precipitate proteins, the supernatant is taken by centrifugation and is diluted; a C18 chromatographic column is used, 0.1% acetic acid aqueous solution and acetonitrile are used as mobile phases for gradient elution; mass spectrometric detection adopts an electrospray ion source negative ion mode and a multiple reaction monitoring mode, the ion pair of thioctic acid is m / z 205.100->171.100, and the ion pair of the internal standard is m / z 210.050->174.100; the peak area ratio is used as a quantitative index, 1 / C 2 weighted linear regression is used to establish a standard curve. The method has the advantages of simple pretreatment, high sensitivity, rapid analysis, strong anti-matrix interference ability, and is suitable for the detection of conventional and hemolytic and hyperlipidemic plasma samples, and can be used for pharmacokinetic research and clinical detection of thioctic acid.

The present application belongs to the technical field of biological detection, and particularly relates to a non-invasive selenium level prediction method based on saliva selenoprotein P detection and application. The present application immunizes mice with heterologously expressed antigen SELENOP (40-194 aa) to generate antibodies, and monoclonal antibodies capable of efficiently recognizing SELENOP are screened and obtained; an ELISA detection method is established using the obtained monoclonal antibodies. The selenium content in human plasma and saliva is detected and analyzed using the detection method and an ICP-MS selenium content detection method, and it is found that there is a significant positive correlation between the three, and a correlation curve between saliva selenoprotein P and human plasma selenium content is established, thereby achieving the purpose of evaluating human selenium level through non-invasive saliva selenoprotein P detection. The technical scheme provided by the present application can be used for large-scale screening and routine health monitoring.

The invention relates to a method for determining the concentration of methimazole in human plasma, which adopts liquid chromatography-tandem mass spectrometry for determination and comprises the following steps: providing a reagent and an instrument; chromatographic conditions and mass spectrometry conditions for analysis are provided, a C18 chromatographic column is used, a 0.1% formic acid aqueous solution / acetonitrile is used for gradient elution, and an electrospray ionization source and positive ion mode is adopted for detection; the method comprises the following steps: preparing a methimazole reference substance series standard solution and a methimazole-d3 internal standard solution; the method comprises the following steps: pretreating a plasma sample by using a derivatization reagent, derivatizing to obtain a sample to be detected, and carrying out LC-MS / MS analysis; determining the linearity and range and the lowest quantitation limit when the method meets the specificity requirement; and measuring the sample and calculating the methimazole concentration in the plasma sample. The method disclosed by the invention is high in sensitivity, small in plasma sample dosage, good in reproducibility, short in analysis time and capable of realizing high-throughput analysis, and can be used for determining a large number of biological samples in methimazole bioequivalence evaluation.

The invention discloses a preparation method of a neonatal ABO hemolytic disease detection simulation specimen in blood transfusion medicine teaching, which comprises the following steps: a, collecting blood plasma or serum of healthy people, and absorbing IgM anti-A, anti-B and anti-AB; b, separating the absorbed plasma or serum, and taking the upper-layer plasma or serum for later use; c, sensitizing corresponding blood type red blood cells, namely absorbing IgG anti-A or anti-B by the A type or B type red blood cells, and preparing a simulation specimen; and d, preserving the specimen. The method disclosed by the invention is simple to operate, and the prepared specimen is a simulated specimen and is used for detecting the neonatal ABO hemolytic disease as an experimental content in blood transfusion medical experiment teaching. The use of the simulation specimen is convenient for students to learn and understand the experiment operation technology in blood transfusion medical experiment teaching, solves the problem that the newborn ABO hemolytic disease detection specimen is not easy to obtain, and meets the requirements of blood transfusion medical experiment teaching.

The invention discloses an Alzheimer's disease risk prediction model and a construction method and application thereof. In the invention, a key factor combination of the Alzheimer's disease, which is composed of FZD6, GRIN2A, TUBA8, RYR3, NDUFS3 and TNF in human plasma, is found for the first time, and an early prediction model which can be used for predicting the incidence probability of the Alzheimer's disease is constructed and processed in combination with a machine learning algorithm, so that the early prediction capability of the Alzheimer's disease is improved; powerful technical support is provided for prevention and early treatment of the Alzheimer's disease.